Evidence map›Paper›PMID 21471514›Full record

ArticleDiabetes2011

O-GlcNAcylation increases ChREBP protein content and transcriptional activity in the liver.

Céline Guinez, Gaëlle Filhoulaud, Fadila Rayah-Benhamed, Solenne Marmier, Céline Dubuquoy, Renaud Dentin, Marthe Moldes, Anne-Françoise Burnol, Xiaoyong Yang, Tony Lefebvre and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Diabetes, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 118 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
118citing papers in PubMed, 1 pooled it
13.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

118 citing papers in PubMed, 1 synthesis or guideline pooled it, 196 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. JHEP reports : innovation in hepatology · 2024
    Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article

58 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 2 countries.

Céline GuinezINSERM, U1016, Institut Cochin, Paris, France.
Gaëlle Filhoulaud
Fadila Rayah-Benhamed
Solenne Marmier
Céline Dubuquoy
Renaud Dentin
Marthe Moldes
Anne-Françoise Burnol
Xiaoyong Yang
Tony Lefebvre
Jean Girard
Catherine Postic
Centre de Gestion Scientifique · FRDélégation Paris 5 · FRInserm · FRInstitut Cochin · FRUniversité Paris Cité · FRUnité de Glycobiologie Structurale et Fonctionnelle · FRYale University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveCarbohydrate-responsive element-binding protein (ChREBP) is a key transcription factor that mediates the effects of glucose on glycolytic and lipogenic genes in the liver. We have previously reported that liver-specific inhibition of ChREBP prevents hepatic steatosis in ob/ob mice by specifically decreasing lipogenic rates in vivo. To better understand the regulation of ChREBP activity in the liver, we investigated the implication of O-linked β-N-acetylglucosamine (O-GlcNAc or O-GlcNAcylation), an important glucose-dependent posttranslational modification playing multiple roles in transcription, protein stabilization, nuclear localization, and signal transduction. RESEARCH DESIGN AND

methodsO-GlcNAcylation is highly dynamic through the action of two enzymes: the O-GlcNAc transferase (OGT), which transfers the monosaccharide to serine/threonine residues on a target protein, and the O-GlcNAcase (OGA), which hydrolyses the sugar. To modulate ChREBP(OG) in vitro and in vivo, the OGT and OGA enzymes were overexpressed or inhibited via adenoviral approaches in mouse hepatocytes and in the liver of C57BL/6J or obese db/db mice.

resultsOur study shows that ChREBP interacts with OGT and is subjected to O-GlcNAcylation in liver cells. O-GlcNAcylation stabilizes the ChREBP protein and increases its transcriptional activity toward its target glycolytic (L-PK) and lipogenic genes (ACC, FAS, and SCD1) when combined with an active glucose flux in vivo. Indeed, OGT overexpression significantly increased ChREBP(OG) in liver nuclear extracts from fed C57BL/6J mice, leading in turn to enhanced lipogenic gene expression and to excessive hepatic triglyceride deposition. In the livers of hyperglycemic obese db/db mice, ChREBP(OG) levels were elevated compared with controls. Interestingly, reducing ChREBP(OG) levels via OGA overexpression decreased lipogenic protein content (ACC, FAS), prevented hepatic steatosis, and improved the lipidic profile of OGA-treated db/db mice.

conclusionsTaken together, our results reveal that O-GlcNAcylation represents an important novel regulation of ChREBP activity in the liver under both physiological and pathophysiological conditions.

Indexed as

AnimalsBasic Helix-Loop-Helix Leucine Zipper Transcription Factorsbeta-N-AcetylhexosaminidasesCell LineCells, CulturedChromatin ImmunoprecipitationFatty LiverHepatocytesHep G2 CellsHumansImmunoblottingImmunoprecipitationLiverMaleMiceMice, Inbred C57BLBasic Helix-Loop-Helix Leucine Zipper Transcription Factorsbeta-N-Acetylhexosaminidaseshexosaminidase CMlxipl protein, mouseN-AcetylglucosaminyltransferasesNuclear ProteinsO-GlcNAc transferaseTranscription Factors

Identifiers

PMID21471514
PMCPMC3292313
OpenAlexW2102824462

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.